生物
卡林
效应器
细胞生物学
泛素连接酶
泛素
COP9信号体
蛋白质降解
泛素蛋白连接酶类
计算生物学
遗传学
生物化学
基因
酶
蛋白酶
肽水解酶类
作者
Cristina Mayor‐Ruiz,Martin G. Jaeger,Sophie Bauer,Matthias Brand,Celine Sin,Alexander Hanzl,André C. Mueller,Jörg Menche,Georg E. Winter
出处
期刊:Molecular Cell
[Elsevier]
日期:2019-08-01
卷期号:75 (4): 849-858.e8
被引量:77
标识
DOI:10.1016/j.molcel.2019.07.013
摘要
Inducing protein degradation via small molecules is a transformative therapeutic paradigm. Although structural requirements of target degradation are emerging, mechanisms determining the cellular response to small-molecule degraders remain poorly understood. To systematically delineate effectors required for targeted protein degradation, we applied genome-scale CRISPR/Cas9 screens for five drugs that hijack different substrate receptors (SRs) of cullin RING ligases (CRLs) to induce target proteolysis. We found that sensitivity to small-molecule degraders is dictated by shared and drug-specific modulator networks, including the COP9 signalosome and the SR exchange factor CAND1. Genetic or pharmacologic perturbation of these effectors impairs CRL plasticity and arrests a wide array of ligases in a constitutively active state. Resulting defects in CRL decommissioning prompt widespread CRL auto-degradation that confers resistance to multiple degraders. Collectively, our study informs on regulation and architecture of CRLs amenable for targeted protein degradation and outlines biomarkers and putative resistance mechanisms for upcoming clinical investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI